DRD2 and glioblastoma: Prabhu et. al. recently found a DRD2 + DRD5- biomarker signature that significantly predicts the sensitivity to ONC201 in pre-clinical models and is associated with improved outcomes in patients treated with ONC201 in a Phase II clinical trial for recurrent glioblastoma [38].